• Petitioner, Kymera Therapeutics in a PGR (PGR2021-00115) of USPN 10,849,980, titled “Methods to Induce Targeted Protein Degradation through Bifunctional Molecules.”  
    • Petitioner BicycleRD in IPR (IPR2020-01569 and IPR2020-01626) of USPNs 8,748,105 and 8,742,070, titled “Method for Selecting a Candidate Drug Compound.” 
    • Petitioner, Eli Lilly & Co., in a PGR (PGR2019-00043) of USPN 10,011,654, entitled “Antibodies Directed to IL-17A/IL-17F Heterodimers.” 
    • Pfizer in securing reissue patent RE47,739 in the U.S. Patent and Trademark Office related to its blockbuster cancer treatment, IBRANCE® (palbociclib).
    • Royalty Pharma in several transactions, including those relating to Risdiplam, Seltorexant, Vertex’s cystic fibrosis treatments, IDHIFA® (enasidenib), ENTYVIO® (vedolizumab), PREVYMIS™ (letermovir), TAZVERIK® (tazemetostat), and PROMACTA® (eltrombopag).
    • A major medical device company as Patent Owner in four IPR proceedings related to patents claiming a minimally invasive continuous glucose monitoring system (CGMS).

     

    • Patent Trial and Appeal Board (PTAB) Bar Association
    • New York Intellectual Property Law Association (NYIPLA)
    • American Chemical Society